Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233947 · ClinicalTrials.gov registry record · Phase 2
Study of AFP464 +/- Faslodex in ER + Breast Cancer
A Phase 2 study, sponsored by Tigris Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01233947 is a Phase 2 study that was terminated before completion, run by Tigris Pharmaceuticals. The registered enrollment target is 7 participants.
The verdict
NCT01233947, a Phase 2 study, was terminated before completion, sponsored by Tigris Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.
Interventions
- DRUG AFP464
- DRUG AFP464 + Faslodex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01233947
The ClinicalTrials.gov registry entry for NCT01233947 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tigris Pharmaceuticals, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AFP464 is the first listed.
NCT01233947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01233947 about?
NCT01233947 is a clinical study titled "Study of AFP464 +/- Faslodex in ER + Breast Cancer". AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.
What is the current status of trial NCT01233947?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2011-05. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01233947?
The interventions under investigation include: AFP464 (DRUG), AFP464 + Faslodex (DRUG).
Who is sponsoring clinical trial NCT01233947?
This trial is sponsored by Tigris Pharmaceuticals, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.